TD Asset Management’s Exagen XGN Stock Holding History

TD Asset Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,235	Closed	-$641K	–	1450
2019 Q4	$641K	Hold	25,235	–	–	﹤0.01%	1195
2019 Q3	$391K	Buy	+25,235	New	+$407K	﹤0.01%	1214

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

TD Asset Management's XGN Position: Q1 2020 in Review

TD Asset Management sold out of Exagen (XGN) in Q1 2020, closing a stake of 25,235 shares — an estimated $641K sold.

TD Asset Management first reported a position in XGN in Q3 2019 and held it in 2 quarters. The position peaked at $641K in Q4 2019. 32 funds tracked by Wall St. Rank hold XGN as of Q1 2020.

TD Asset Management reported no remaining Exagen position as of Q1 2020 after selling out during the quarter.
TD Asset Management sold 25,235 Exagen shares in Q1 2020, an estimated $641K.
TD Asset Management first reported a position in Exagen in Q3 2019 and held it in 2 quarters.
TD Asset Management's Exagen position peaked at $641K in Q4 2019.
32 funds tracked by Wall St. Rank held Exagen as of Q1 2020.

Based on TD Asset Management's 13F filing for Q1 2020, filed 15 May 2020.